Lynda Charters

Options facilitate increased durability for patients with retinal degeneration.

According to a team of French investigators, every patient hospitalized with severe COVID-19 cases in their study had retinal and choroidal anomalies on indocyanine green angiography and optical coherence tomography images that were possibly related to the virus.

In a poster presented at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Mark Wieland, MD, noted that the Port Delivery System with ranibizumab provides drug delivery over an extended period.

During a presentation at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Veeral Sheth, MD, presented research that found faricimab, a bispecific monoclonal antibody, provided sustained retinal stability in patients with diabetic macular edema (DME) compared with other retinal treatments.

Speaking at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Ines Lains, MD, PhD, explained that the mechanisms of AMD progression currently remain poorly understood and the tools to predict and halt progression are limited.

In a presentation at the American Academy of Ophthalmology’s 2021 annual meeting in New Orleans, Nathan Hall, BS, MS, pointed out that an epidemiologic analysis of malignant ocular surface tumors found significant differences in geographic prevalence rates in the United States.

During a presentation at the American Academy of Ophthalmology 2021 annual meeting, Denise Freitas, MD, reported that the ocular findings in infants with congenital Zika virus syndrome were similar among the affected infants and occurred frequently. The most prevalent of the findings was optic nerve pallor.

Roger A. Goldberg, MD, MBA, speaking at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, noted that small misalignments in the plunger can lead to possible overdosing.

Felipe Medeiros, MD, in a presentation at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, noted that a phase 3 clinical extension study of the bimatoprost implant found that patients’ IOP was lowered and stayed low with no additional treatment or changes in their visual fields.

Shady Awwad, MD, in a presentation at the American Academy of Ophthalmology’s 2021 annual meeting in New Orleans, pointed out that the application of mitomycin C after corneal crosslinking does not prevent development of corneal haze after the procedure and actually contributes to development of more corneal haze.

tPA treatment could provide benefits for patients with central retinal artery occlusion.

During the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dilsher Dhoot, MD, reported the results of the KESTREL and KITE in which brolucizumab was compared with aflibercept for treating diabetic macular edema.

Options facilitate increased durability for patients with retinal degeneration.

A team of investigators from the University of Michigan may have unlocked a potential new recipe for counteracting the impact that COVID-19 has on patients with underlying disease processes such as type 2 diabetes.

The investigators reported the following most prominent cognitive deficits: processing speed, executive functioning, and phonemic fluency among others.

Investigators find that long-term ocular complications require further observation.

The FDA approved Ocular Therapeutix Inc.’s Supplemental New Drug Application (sNDA) that further extends Dextenza’s (dexamethasone ophthalmic insert) 0.4 mg indications, the company announced Monday.

During the American Society of Retina Specialists 2021 annual meeting, David Boyer, MD, told attendees that pegcetacoplan used to treat geographic atrophy proved to be well tolerated by patients in the phase 3 DERBY and OAKS studies.

In a presentation at the American Society of Retina Specialists 2021 annual meeting, Arshad Khanani, MD, MA, noted that investigators achieved results similar to those in patients treated with monthly ranibizumab injections for neovascular age-related macular degeneration.

Speaking at the American Society of Retina Specialists 2021 annual meeting, Richard B. Rosen, MD, DSc (Hon) noted that clinical OCT and offers a new clinical biomarker for tracking the onset and progression of retinal vascular disease and the response to therapy.

During a presentation at American Society of Retina Specialists 2021 annual meeting in San Antonio, Sunir Garg, MD, presented data showing that universal masking does not seem to increase the risk of developing endophthalmitis, and it may cause a reduction in culture positive endophthalmitis.

During a presentation at the American Society of Retina Specialists 2021 annual meeting in San Antonio, Texas, Yoshihiro Yonekawa, MD, warned of the potential risk of endophthalmitis with the use of implantable MIGS devices.

Speaking at the American Society of Retina Specialists 2021 annual meeting in San Antonio, Rishi P. Singh, MD, provided results of the VISTA and VIVID studies, and he pointed out that the findings could help physicians set expectations of DME therapy.

During a presentation at the American Society of Retina Specialists 2021 annual meeting in San Antonio, W. Lloyd Clark, MD, presented results of the PANORAMA Study. The focus of the study, Clark said, was to identify the factors that increase the risk of complications in patients with nonproliferative diabetic retinopathy to provide information for making decisions on treatment choices.

Researchers set out to identify clinical and anatomic factor-associated vision loss in eyes with treatment-naïve DME and good initial VA.

In PIONEER study, investigators outline successes.

A study in the United Arab Emirates reported a possible link between adverse ocular events and a COVID-19 vaccination.

Investigators find that wearable aid offers improved mobility.

Anterior uveitis therapy offers anti-inflammatory effect after dosing is stopped.

During a presentation at the EURETINA 2021 Virtual Congress, Prof. Ben Burton detailed how dry AMD patients treated with photobiomodulation therapy have seen improvements in best-corrected visual acuity 9 months after treatment.